NCT00518284View on ClinicalTrials.gov

Prevention of Restenosis Following Revascularization

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2009

Conditions
Vascular Disease, Peripheral
Interventions
DRUG

Nanoparticle Paclitaxel

Nanoparticle albumin-bound paclitaxel, 45 mg/m\^2.

Trial Locations (7)

32605

Vascular & Interventional Physicians, Gainsville

45219

Lindner Clinical Trials Center, Cincinnati

48507

Michigan Vascular Research Center, Flint

52803

Midwest Cardiovascular Research Foundation, Davenport

95817

UC Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400, Sacramento

07666

Holy Name Hospital, Teaneck

02903

Rhode Island Hospital, Providence

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY